Compare SIDU & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | TLSA |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 155.2M |
| IPO Year | 2021 | 2017 |
| Metric | SIDU | TLSA |
|---|---|---|
| Price | $2.69 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 129.0K |
| Earning Date | 05-14-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,672,646.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $0.73 |
| 52 Week High | $5.39 | $2.60 |
| Indicator | SIDU | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 44.40 |
| Support Level | $0.89 | $1.27 |
| Resistance Level | $4.40 | $1.59 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 65.76 | 30.00 |
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.